Kyriakos P. Papadopoulos, MD, et al. Phase 1, First-in-Human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid (INNATE). Presented at teh ASCO Annual Meeting 2021. | Jounce Therapeutics

Kyriakos P. Papadopoulos, MD, et al. Phase 1, First-in-Human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid (INNATE). Presented at teh ASCO Annual Meeting 2021.